After signing up, you'll start to receive regular news updates from us.
NBCC has Chosen OncoDNA for OncoDEEP Solution
Complete the form below to unlock access to ALL audio articles.
Belgium based OncoDNA SA, has recently announced a supplier agreement with NBCC (National Blood and Cancer Center in Riyadh, Saudi Arabia) to bring affordable and state-of-the-art DNA sequencing technologies to the GCC countries and thus help oncologists make the best decisions in treatment choice.
NBCC has chosen OncoDNA as its preferred supplier of clinical grade molecular diagnostics using the OncoDEEP DX and Clinical cancer panels. The collaboration agreement with OncoDNA will enable GCC physicians to access medical innovations based on next gen sequencing, providing them with clinically relevant interpretations of patients' tumours.
OncoDNA’s aim is to provide medical innovations based on targeted sequencing or the complete sequencing of tumour genomes, in order to assist medical doctors in their treatment choices and/or provide better monitoring of the evolution of patient tumours. OncoDNA is a subsidiary of Bio.Be, an affiliated company of IPG (Institute of Pathology and Genetics) in Belgium.
NBCC (National Blood and Cancer Center) is a specialized centre for diagnosing and treating blood diseases and cancers. One of the goals of this private institution is to bring new high value technologies from around the world to Saudi Arabia and its neighbouring countries, at an affordable price.
Mr Jean-Pol Detiffe, founder and CEO of OncoDNA, said: “With this supplier agreement, OncoDNA is continuing to fulfil its ambitions,using innovations based on the targeted or complete sequencing of tumour genomes to help medical doctors make the right treatment choice and better monitor tumour development in the patient. More interestingly, we have are shown that our OncoDEEP solution can be exported all over the world.”
At NBCC, Dr Ali Al-Shanqeeti, Chief Executive Officer, commented: “This agreement with OncoDNA will enable GCC physicians to access molecular diagnostic information based on next gen sequencing for their treatment decisions and demonstrate the use of such information to improve patient outcomes”.
